Yasuo Uchida, Ph.D. (内田　康雄)

Personal Information

Name:               Yasuo Uchida, Ph.D.
Sex:                  Male
Date of birth:      December 12, 1983
Place of birth:     Oyama, Tochigi pref, Japan
Nationality:         Japanese
Office address:   Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University
                        6-3 Aoba, Aramaki, Aoba-ku, Sendai, 980-8578, JAPAN.
Phone:              022‐795‐6832 (International +81‐22‐795‐6832)
Fax:                  022‐795‐6886 (International +81‐22‐795‐6886)
Email:               yasuo.uchida.c8@tohoku.ac.jp

Dr. Uchida is currently a lecturer of Tohoku University. In Jan 2012, he received a Ph.D. degree from the Graduate School of Pharmaceutical Sciences, Tohoku University. He has a lot of achievements in the field of the LC-MS/MS-based central nervous system (CNS) barrier research and opened a new field of “Pharmacoproteomics (PPx)”. The transporter study of the CNS barriers is one of his interests, and he is going to comprehensively and rationally clarify (1) what transporter proteins are expressed with the information of absolute abundance, apical/basolateral localization and post-translational modification by the comprehensive absolute quantification method he established, (2) what role they have physiologically and pharmacokinetically by comprehensive transport assay method he established, and (3) how they change in the CNS disorders by highly reliable FFPE proteomics (FFPE-PCT-SWATH) he established. One of his papers, Pharm Res 25:1469-1483 (2008) has been awarded as “Pharmaceutical Research Meritorious Manuscript Award”, and another one, J. Neurochem 117:333-345 (2011), has been also cited 400 times for 8 years and selected as the most cited paper in 2013 in the Journal of Neurochemistry.

Major accomplishments

  1. Development of LC-MS/MS-based simultaneous absolute quantification method for functional proteins including transporters, enzymes, receptors and channels, etc (= Quantitative Targeted Absolute Proteomics (QTAP)).
  2. Elucidation of absolute expression levels of more than 150 functional proteins including ABC, SLC transporters, CYP, UGT, GST, SULT enzymes, some receptors at human, monkey, marmoset, rat and mouse blood-brain barrier (BBB).
  3. Pharmacoproteomics (PPx): Establishment of a reconstruction method of in vivo transport activity for ABC transporters at the BBB by integrating absolute expression level of transporter at the BBB (mol) and the transport activity per transporter (transport rate / mol).
  4. PPx: Establishment of a prediction method of drug distribution in human brain (Kp,brain and Kp,uu,brain) from in vitro experiments combined with QTAP and pharmacokinetics.
  5. Development of a comprehensive substrate/non-substrate screening method for transporters by the transport assay using the mixture of multiple compounds (LC-MS/MS Cocktail Method).
  6. Development of highly precise and comprehensive label free absolute quantification method by highly precise SWATH-MS (SWATH-MS + in silico data/peptide selection criteria).
  7. Development of reliable and comprehensive quantitative proteomics method for formalin-fixed paraffin-embedded (FFPE) tissue by means of Pressure Cycling Technology (PCT)-aided sample process and SWATH-MS (FFPE-PCT-SWATH).
  8. Elucidation of the pathophysiological molecular mechanisms for the transport systems at the CNS barriers by the comprehensive quantitative phosphoproteomics (PhosphoTransportSome).

Education

  1. April 2002 – March 2006： Faculty of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (B.S. awarded March 2006)
  2. April 2006 – March 2008： Master course program, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.S. awarded March 2008)
  3. April 2008 – March 2010： Ph.D. program, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
  4. January 2012： Ph.D. awarded in Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (Advisor: Prof. Tetsuya Terasaki)

Research and Professional Experience

  1. April 2008 – March 2010： Research Fellow (DC1) of the JSPS (Japan Society for the Promotion of Science)
  2. April 2010 – January 2012： Research Associate, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
  3. February 2012 – August 2018： Assistant professor, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
  4. April 2014 – March 2016： Postdoctral Research Fellow of the JSPS for Research Abroad (a visiting scientist in Professor Ruedi Aebersold laboratory, Institute of Molecular Systems Biology, ETH Zurich, Switzerland)
  5. September 2018 – Present： Lecturer, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan

Handling editor, Editorial Advisary Board, Scientific Advisor & Editorial Assistant of International Journal

  1. Handling Editor, Journal of Neurochemistry (Oct 2019 – Present)
  2. Editorial Advisary Board, Molecular Pharmaceutics (Oct 2019 – Present)
  3. Editorial Advisary Board, Journal of Pharmaceutical Sciences (Oct 2019 – Present)
  4. Editorial Advisary Board, Drug Metabolism and Pharmacokinetics (April 2020 – Present)
  5. Scientific Advisor, Journal of Pharmaceutical Sciences (Apr 2013 – Sep 2019)
  6. Editorial Assistant of Prof Tetsuya Terasaki, Associate Editor, Journal of Pharmaceutical Sciences (January 2008 – March 2014)
  7. Editorial Assistant of Prof Tetsuya Terasaki, Handling Editor, Journal of Neurochemistry (January 2009 – March 2014)

Awards

  1. The Pharmaceutical Society of Japan Award for Young Scientists, Mar 2020
  2. Dean Award 2018 in Graduate School of Pharmaceutical Sciences, Tohoku University, July 2018 (Award for the person getting the largest amount of research budget)
  3. The 17th Intelligent Cosmos Award for Young Scientists, May. 2018
  4. JSSX 32nd annual conference, Excellent Oral Presentation Award, Nov. 2017
  5. Dean Award 2017 in Graduate School of Pharmaceutical Sciences, Tohoku University, July 2017 (Award for the person getting the largest amount of research budget)
  6. The 30th Inoue Research Award for Young Scientists, Feb. 2014
  7. APSTJ 28th Annual Conference, Best Presentation Award, May 2013
  8. AAPS Pharmaceutical Research Meritorious Manuscript Award, Nov. 2010
  9. 8th Cerebral Vascular Biology International Conference, Outstanding Presentation Award, July 2009
  10. APSTJ 24th Annual Conference, SNPEE Most Impressive Laboratory Award, May 2009
  11. APSTJ 23rd Annual Conference, Best Presentation Award, May 2008
  12. 7th Cerebral Vascular Biology International Conference, Travel Award, Jun 2007
  13. 3rd Tohoku University Bioscience Symposium, Best Poster Presentation Award, May 2006
  14. Tohoku university president prize, March 2006

Membership of Academic Societies

  1. International Society for Neurochemistry
  2. International Brain Barriers Society
  3. Human Proteome Organization
  4. International Society for the Study of Xenobiotics
  5. American Association of Pharmaceutical Scientists
  6. Japanese Society for the Study of Xenobiotics
  7. Pharmaceutical Society of Japan
  8. Academy of Pharmaceutical Sciences and Technology, Japan
  9. Japan Transporter Research Association

研究費の採択実績（代表のみ）

  1. 基盤研究（B）, 2020年4月–2023年3月
  2. 新学術領域研究（公募研究：生命金属科学）, 2020年4月–2022年3月
  3. 新学術領域研究（公募研究：分子夾雑の生命化学）, 2020年4月–2022年3月
  4. 国際共同研究加速基金（国際共同研究強化(A)）, 2019年–2022年
  5. 挑戦的研究(萌芽), 2019年4月–2021年3月
  6. 上原記念生命科学財団: 平成３０年度 研究奨励金, 2019年3月–2020年4月
  7. 新学術領域研究（公募研究：分子夾雑の生命化学）, 2018年4月–2020年3月
  8. 若手研究(A), 2016年4月–2020年3月
  9. 持田記念研究助成金, 2018年–2019年
  10. 中冨健康科学振興財団研究助成金, 2017年3月–2018年3月
  11. 挑戦的萌芽研究, 2016年4月–2018年3月
  12. ｲﾝﾃﾘｼﾞｪﾝﾄ・ｺｽﾓｽ学術振興財団研究助成, 2018年
  13. 武田科学振興財団薬学系研究奨励, 2016年–2018年
  14. 海外特別研究員奨励費, 2014年4月–2016年3月
  15. 若手研究(B), 2011年4月–2014年3月
  16. JST復興促進プログラムA-STEP探索タイプ, 2012年–2013年
  17. 特別研究員奨励費DC1, 2008年4月–2010年3月

Original Articles（主要なもののみ）

  1. Uchida Y (corresponding author), Sasaki H, Terasaki T. Establishment and validation of highly accurate formalin-fixed paraffin-embedded quantitative proteomics by heat-compatible pressure cycling technology using phase-transfer surfactant and SWATH-MS. Sci Rep, 2020 Jul;10(1):11271.
  2. Uchida Y (corresponding author), Yagi Y, Takao M, Tano M, Umetsu M, Hirano S, Usui T, Tachikawa M, Terasaki T. Comparison of Absolute Protein Abundances of Transporters and Receptors among Blood-Brain Barriers at Different Cerebral Regions and the Blood-Spinal Cord Barrier in Humans and Rats. Mol Pharm, 2020 Jun;17(6):2006-2020.
  3. Y Uchida (corresponding author), Goto R, Takeuchi H, Luczak M, Usui T, Tachikawa M, Terasaki T. Abundant expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1 and xCT transporters in blood-arachnoid barrier of pig, and polarized localizations at CSF- and blood-facing plasma membranes. Drug Metab Dispos, 2020 Feb;48(2):135-145.
  4. Hoshi Y, Uchida Y (corresponding author), Kuroda T, Tachikawa M, Couraud PO, Suzuki T, Terasaki T. Distinct roles of ezrin, radixin and moesin in maintaining the plasma membrane localizations and functions of human blood-brain barrier transporters. J Cereb Blood Flow Metab, 2020 Jul;40(7):1533-1545.
  5. Uchida Y (co-first author), Hoshi Y, Tachikawa M, Ohtsuki S, Couraud PO, Suzuki T, Terasaki T. Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood-brain barrier. J Cereb Blood Flow Metab., 2020 Feb;40(2):420-436.
  6. Ochiai Y, Uchida Y, Tachikawa M, Couraud PO, Terasaki T. Amyloid beta(25-35) impairs docosahexaenoic acid efflux by down-regulating fatty acid transport protein 1 (FATP1/SLC27A1) protein expression in human brain capillary endothelial cells. J Neurochem., 2019 Aug;150(4):385-401.
  7. Y Uchida (corresponding author), T Sumiya, M Tachikawa, T Yamakawa, S Murata, Y Yagi, K Sato, A Stephan, K Ito, S Ohtsuki, PO Couraud, T Suzuki, and T Terasaki. Involvement of claudin-11 in disruption of blood-brain, -spinal cord and -arachnoid barriers in multiple sclerosis. Mol Neurobiol, 2019 Mar;56(3):2039-2056.
  8. Akazawa T, Uchida Y, Miyauchi E, Tachikawa M, Ohtsuki S, Terasaki T. High Expression of UGT1A1/1A6 in Monkey Small Intestine: Comparison of Protein Expression Levels of Cytochromes P450, UDP-Glucuronosyltransferases, and Transporters in Small Intestine of Cynomolgus Monkey and Human. Mol Pharm. 2018; 15(1): 127-140.
  9. Zhang Z, Uchida Y, Hirano S, Ando D, Kubo Y, Auriola S, Akanuma SI, Hosoya KI, Urtti A, Terasaki T, Tachikawa M. Inner Blood-Retinal Barrier Dominantly Expresses Breast Cancer Resistance Protein: Comparative Quantitative Targeted Absolute Proteomics Study of CNS Barriers in Pig. Mol Pharm. 2017; 14(11): 3729-3738.
  10. Uchida Y (co-first author), Hoshi Y, Tachikawa M, Ohtsuki S, Terasaki T. Actin filament-associated protein 1 (AFAP-1) is a key mediator in inflammatory signaling-induced rapid attenuation of intrinsic P-gp function in human brain capillary endothelial cells. J Neurochem. 2017; 141(2): 247-262.
  11. Ochiai Y, Uchida Y, Ohtsuki S, Tachikawa M, Aizawa S, Terasaki T. The blood-brain barrier fatty acid transport protein 1 (FATP1/SLC27A1) supplies docosahexaenoic acid to the brain, and insulin facilitates transport. J Neurochem. 2017; 141: 400-412. This paper was featured as an Editorial Comment in the Journal of Neurochemistry as “FATP1 is a major route at the human blood-brain barrier for the supply of docosahexaenoic acid (DHA) into the brain”.
  12. Akazawa T, Uchida Y, Tachikawa M, Ohtsuki S, Terasaki T. Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine. Mol Pharm, 13(7), 2016, 2443-2456.
  13. Uchida Y, Toyohara T, Ohtsuki S, Moriyama Y, Abe T, Terasaki T. Quantitative targeted absolute proteomics for 28 transporters in brush-border and basolateral membrane fractions of rat kidney, J Pharm Sci, 105(2), 2016, 1011-1016.
  14. Uchida Y, Ito K, Ohtsuki S, Kubo Y, Suzuki T, Terasaki T. Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells. J Neurochem, 134(1), 2015, 97-112.
  15. Uchida Y, Zhang Z, Tachikawa M and Terasaki T. Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: comparison with a human specimen. J Neurochem, 134(6), 2015, 1104-15.
  16. Uchida Y (corresponding author), Ohtsuki S, Kamiie J, Ohmine K, Iwase R, Terasaki T. Quantitative targeted absolute proteomics for 28 human transporters in plasma membrane of Caco-2 cell monolayer cultured for 2, 3, and 4 weeks. Drug Metab Pharmacokinet, 30(2), 2015, 205-208.
  17. Uchida Y (co-first author), Sadiq MW, Hoshi Y, Tachikawa M, Terasaki T, Hammarlund-Udenaes M. Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for Blood-Brain Barrier Transport. PLoS One,10(5), 2015 ,e0118638.
  18. Uchida Y, Ohtsuki S, Terasaki T. Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models. Drug Metab Dispos, 42(10), 2014, 1719-1726.
  19. Uchida Y, Wakayama K, Ohtsuki S, Chiba M, Ohe T, Ishii Y, Terasaki T. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys. J Pharmacol Exp Ther, 350(3), 2014, 578-588.
  20. Y Uchida, M Tachikawa, W Obuchi, Y Hoshi, Y Tomioka, S Ohtsuki, T Terasaki. A Study Protocol for Quantitative Targeted Absolute Proteomics (QTAP) by LC-MS/MS: Application for Inter-Strain Differences in Protein Expression Levels of Transporters, Receptors, Claudin-5, and Marker Proteins at the Blood-Brain Barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS, 10, 21 (2013).
  21. Y Hoshi, Y Uchida, M Tachikawa, T Inoue, S Ohtsuki, T Terasaki. Quantitative atlas of blood-brain barrier transporters, receptors and tight junction proteins in rats and common marmoset. J. Pharm. Sci., 102, 3343-3355 (2013). This paper was selected as Top 10 Downloaded Article in the Journal of Pharmaceutical Sciences in 2013.
  22. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF. Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-gp, Bcrp, and P-gp/Bcrp Knockout Mice. Drug Metab. Dispos., 40, 1164-1169 (2012).
  23. Akanuma S, Uchida Y, Ohtsuki S, Kamiie J, Tachikawa M, Terasaki T, Hosoya K. Molecular-weight-dependent, anionic-substrate-preferential transport of β-lactam antibiotics via multidrug resistance-associated protein 4. Drug Metab. Pharmacokinet., 26, 602-611 (2011).
  24. Akanuma S, Uchida Y, Ohtsuki S, Tachikawa M, Terasaki T, Hosoya K. Attenuation of prostaglandin E2 elimination across the mouse blood-brain barrier in lipopolysaccharide- induced inflammation and additive inhibitory effect of cefmetazole. Fluids Barriers CNS, 8, 24 (2011).
  25. Y. Uchida, S. Ohtsuki, J. Kamiie, T. Terasaki. Blood-brain barrier (BBB) pharmacoproteomics (PPx): reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J. Pharmacol. Exp. Ther., 339, 579-588 (2011).
  26. Y. Uchida (co-first author), R. Shawahna, X. Decleves, S. Ohtsuki, S. Yosif, S. Dauchy, A. Jacob, F. Chassoux, C. Daumas, P.O. Couraud, T. Terasaki, J.M. Scherrmann. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm., 8, 1332-1341 (2011).
  27. Y Uchida, S Ohtsuki, Y Katsukura, C Ikeda, T Suzuki, J Kamiie and T Terasaki. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem., 117, 333-345 (2011). This paper has been cited 400 times for 8 years until 2019 (based on Web of Science), and selected as the most cited paper in 2013 in the Journal of Neurochemistry, and top 20 most cited paper during 3 years between 2017 and 2019.
  28. K Ito, Y Uchida, S Ohtsuki, S Aizawa, H Kawakami, Y Katsukura, J Kamiie, and T Terasaki. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J. Pharm. Sci., 100, 3939-3950 (2011).
  29. Uchida Y, Kamiie J, Ohtsuki S and Terasaki T. Multichannel Liquid Chromatography-Tandem Mass Spectrometry Cocktail Method for Comprehensive Substrate Characterization of Multidrug Resistance-Associated Protein 4 Transporter. Pharm. Res., 24, 2281-2296 (2007).

Reviews（主要なもののみ）

  1. Y Uchida. Physiological and Pharmacological Roles of “Blood-Arachnoid Barrier”, a New Interface of Central Nervous System: Importance of Quantitative Proteomics to Open up a New World. Proteome Letters,　5, 2020, in press (Japanese).
  2. Y Uchida. Prediction of drug concentration in human brain based on elucidation of molecular mechanisms of four CNS barriers and establishment of a new field of drug development for CNS disorder. Yakuji-Nippo, 2020 (Japanese).
  3. Y Uchida. Next generation quantitative proteomics-based identification of novel tight junction protein in CNS barrier and its involvement in disruption of CNS barriers in multiple sclerosis. farmacia, 55(4), 320-324, 2019 (Japanese).
  4. Y Uchida. Uniprot database. farmacia, 55(4), 335-335, 2019 (Japanese).
  5. Y Uchida, T Usui and T Terasaki. Investigation of molecular mechanisms regulating the efflux function of P-glycoprotein at the blood-brain barrier in CNS disorders and New horizon toward CNS-barrier-targeting drug development. Igaku-no-Ayumi, 271(1), 104-111, 2019 (Japanese).
  6. Y Uchida. Elucidation of drug transport system at human blood-brain barrier based on the reconstruction of transport molecular crawding system. CMCB NEWS LETTER, 2019 (Japanese).
  7. Y Uchida. What is SWATH-MS?: Next generation quantitative proteomics combining a superior quantitative accuracy, sensitivity and comprehensiveness. Yakuzaigaku「Recent Topics」, 78(5), 228-234, 2018 (Japanese).
  8. T Yoneyama, Y Uchida, M Tachikawa, S Ohtsuki and T Terasaki. Mass Spectrometry Based Approach for Biomarker Research. Idenshi-Igaku MOOK, 29, 72-81, 2015 (Japanese).
  9. M Tachikawa, Y Uchida, T Terasaki. Blood-Brain Barrier (DOI：10.14931/bsd.3373), IN On-line Dictionary ” Brain Science Dictionary”. 2015 (Japanese).
  10. Y Uchida. 9 years’ pharmacokinetic prediction research, and study abroad toward the prediction of drug efficacy and side effect. DMPK News Letter, 29(3), 2014, 14-15 (Japanese).
  11. T Terasaki, Y Uchida, S Ohtsuki, M Tachikawa. Quantitative Targeted Absolute Proteomics for the New Horizon of DDS Research. Progress in Drug Delivery System XXII, 2013, 7-12 (Japanese).
  12. Y Uchida, K Sato, H Kuroda, Y Hoshi, M Tachikawa, T Terasaki. Quantitative targeted absolute proteomics in blood-brain barrier. Vascular Biology & Medicine, 14(4), 2013, 399-409 (Japanese).
  13. M Tachikawa, Y Uchida, T Terasaki. Quantitative targeted absolute proteomics (QTAP)-based rational research on the human blood-brain barrier transport. Drug Delivery System, 28, 270-278 (2013) (Japanese).
  14. Y Uchida, M Tachikawa, T Terasaki. Reconstruction of blood-brain barrier transport function from in vitro system based on quantitative targeted absolute proteomics (QTAP). Cell Technology, 32, 955-961 (2013) (Japanese).
  15. Y Uchida, M Tachikawa, Y Hoshi, T Terasaki. Quantitative absolute expression profile of blood-brain barrier transportsome : similarity and difference between animal species, strains and wild/knockout mice. Brain 21, Vol.16, No.3, 46-52 (2013) (Japanese).
  16. Tachikawa M, Uchida Y, Terasaki T. Multi-disciplinary Research Approaches on the Brain Barrier Transport System, a Dynamic Interface. Brain Nerve, 65, 121-136 (2013) (Japanese).
  17. Y Uchida. LC-MS/MS-based blood-brain barrier transporter study. Drug Delivery System, 27, 316-317 (2012). (Japanese).
  18. Y Uchida, M Tachikawa, T Terasaki. New insight of transporter research based on quantitative targeted absolute proteomics. Cell Technology, 31, 587-588 (2012) (Japanese).
  19. M Tachikawa, Y Uchida, S Ohtsuki, T Terasaki. Physiological function and expression of transporters at human blood-brain barrier based on quantitative targeted absolute proteomics. Brain 21, 14, 336-342 (2011) (Japanese).
  20. Ohtsuki S, Uchida Y, Kubo Y, Terasaki T. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: Methodology, advantages, strategy, and prospects. J. Pharm. Sci., 100, 3547-3559 (2011).
  21. Y Uchida, S Ohtsuki and T Terasaki. Pharmacoproteomics (PPx)-based blood-brain barrier research. IdenshiIgaku MOOK, 19, 148-154 (2011) (Japanese).
  22. Y Uchida. Laboratory Introduction in University; Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University. Kenyaku news in Miyagi Pref. Pharmaceutical Association, 404, 4-5, (2010) (Japanese).
  23. S Ohtsuki, Y Uchida and T Terasaki. Molecular mechanism of blood-brain barrier transport system and CNS disorders. Molecular Cerebrovascular Medicine, 9, 257-264 (2010) (Japanese).
  24. Y Uchida, S Ohtsuki and T Terasaki. Role of ABC transporters at blood-brain barrier in drug therapy. Clinical Neuroscience, 26, 1107-1110 (2008) (Japanese).
  25. Y Uchida, J Kamiie, S Ohtsuki, M Odagiri and T Terasaki. Transport of uremic toxins at blood-brain barrier and kidney. Kidney and Dialysis, 62, 327-333 (2007) (Japanese).

Book chapters（主要なもののみ）

  1. Y Uchida, R Goto, T Usui, M Tachikawa and T Terasaki. Blood-arachnoid barrier as a dynamic physiological and pharmacological interface between cerebrospinal fluid and blood. Springer, in press
  2. Uchida Y, Tachikawa M. Chapter 10, Pharmacoproteomics. IN Essential Manual for Pharmaceutical Experiment, Y Watanabe, Y Deguchi and K Ito (Ed.), Nankodo Co., Ltd. Tokyo, pp312-324, 2014 (Japanese).
  3. M Tachikawa, Y Uchida, S Ohtsuki and T Terasaki. Recent progress in blood-brain barrier and blood-CSF barrier transport research: Pharmaceutical relevance for drug delivery to the brain. IN Drug Delivery to the Brain - Physiological Concepts, Methodologies and Approaches, Margareta Hammarlund-Udenaes, Elizabeth de Lange and Robert Thorne (Ed.), Springer, pp 23-62, 2014.
  4. Y Uchida, M Tachikawa, S Ohtsuki and T Terasaki. Blood-brain barrier (BBB) pharmacoproteomics: a new research field opened up by quantitative targeted absolute proteomics (QTAP). IN Drug Delivery to the Brain - Physiological Concepts, Methodologies and Approaches, Margareta Hammarlund-Udenaes, Elizabeth de Lange and Robert Thorne (Ed.), Springer, pp 63-100, 2014.
  5. Y Uchida, S Ohtsuki, K Ohmine and T Terasaki. The role of drug transporters at blood-brain barrier. IN The World of Transportsome -From Headstream of Membrane Transport Research to the Future-, Y Kanai, H Takeshima, Y Mori and Y Kubo (Ed.), Kyoto Hirokawa Publishing Inc. Tokyo, pp282-290 (2011) (Japanese).

Invited lectures

  1. Uchida Y., Quantitative proteomics-based elucidation of transport function and pathological molecular mechanism at the blood-brain barrier, The 140th annual conference of the Pharmaceutical Society of Japan, March 27, 2020, Kyoto, Japan
  2. Uchida Y., Blood-brain barrier P-glycoprotein activation as a new potential therapy of brain infarct, 34th JSSX annual conference, December 12, 2019, Tsukuba, Japan
  3. Uchida Y., Next generation quantitative proteomics "SWATH-MS", The seminar of Graduate School of Pharmaceutical Sciences, University of Tokyo, June 5th, 2019, Tokyo, Japan
  4. Uchida Y., Key Issues and Our Solutions in Transporter Proteomics, The Seminar of University of Eastern Finland, School of Pharmacy, May 7th, 2019, Kuopio, Finland
  5. Uchida Y., Next generation quantitative proteomics SWATH-based investigation for the disruption mechanism of CNS barriers in multiple sclerosis, The 40th Symposium on Biomembrane-drug interaction, October 19, 2018, Sendai, Japan
  6. Uchida Y., Membrane Enrichment and Sample Preparation for Targeted Proteomics, ISSX Workshop on LC-MS proteomics, September 27, 2018, Cambridge, MA, USA
  7. Uchida Y., Regulation mechanism and prediction of CNS drug penetration for drug development of CNS disorders based on next generation quantitative proteomics, Seminar in Takeda Pharmaceutical Shonan Institute, September 13, 2018
  8. Uchida Y., Comprehensive and accurate biomarker discovery/quantification by means of SWATH-MS proteomics, 45th BMS conference, July 4-6, 2018, Iwanuma, Miyagi, Japan
  9. Uchida Y., Next generation quantitative proteomics “SWATH-MS”, Mass Spectrometry and Proteomics 2018 (MSP2018), Luncheon Seminar、May 15-18, 2018, Osaka, Japan
  10. Uchida Y., LC-MS/MS-based research for Blood-Brain Barrier and Malignant Brain Tumor. Seminar in Institute for Research in Biomedicine, University of Barcelona, Barcelona, Spain, Jun 8, 2017
  11. Y Uchida. Regulatory mechanism of transport function of P-glycoprotein at blood-brain barrier. The 12th Annual conference of Japan Transporter Research Association, July 8-9, 2017, Sendai, Japan.
  12. Y Uchida. Recommendation toward study abroad: Two years in Switzerland. The alumni association seminar in Faculty of Pharmacy, Tohoku University, April 6, 2017.
  13. Y Uchida. Basis and Application of Next Generation Quantitative Proteomics “SWATH-MS”. The 12th Tohoku University Interdisciplinary Science Frontier Research Institute (FRIS) seminar, Aug 10, 2016, Sendai, Japan.
  14. Y Uchida. Reconstruction of brain distribution of P-gp substrate by integrating P-gp absolute abundance, its intrinsic transport activity and unbound fraction, and the analysis of factors contributing to species differences in the brain distribution. JSSX 10th short course, May 12, 2016, Senri, Japan.
  15. Y Uchida. Reconstruction of in vivo transport function of ABC transporter in blood-brain barrier by using quantitative proteomic technology. Kumamoto University Seminar, Kumamoto, Japan, Dec 2, 2013.
  16. Y Uchida. Prediction of drug distribution into the brain from in vitro based on transporter protein expression levels. The 36th annual meeting of JSSX danwakai, Hamamatsu, Japan, Nov 7-8, 2013.
  17. Y Uchida. IVIVE of Transporters - Part III (IVIVE of transporters). The 3rd Simcyp Tokyo Workshop, Tokyo, Japan, Nov 16, 2012.
  18. Y Uchida. Pharmacoproteomics (PPx): A Rational Application of Quantitative Targeted Absolute Proteomics for Blood-Brain Barrier Research and Malignant Brain Tumors. UCSF Seminar, San Francisco, USA, Sep, 2012.
  19. Y Uchida. A Rational Application of Quantitative Targeted Absolute Proteomics for Blood-Brain Barrier Research and Malignant Brain Tumors. Seminar in Broad Institute, Boston, USA, Sep, 2012.
  20. Y Uchida, Y Katsukura, C Ikeda, K Ito, T Suzuki, S Ohtsuki, J Kamiie and T Terasaki. A Rational Application of Quantitative Targeted Absolute Proteomics for Blood-Brain Barrier Research. Seminar in Sookmyung Women’s University, Seoul, Korea, Dec 10, 2010.
  21. Y Uchida. New drug discovery research opened up by protein quantification. Seminar in Tohoku University Young Scientist Club, Sendai, Japan, Aug 21, 2010.
  22. Y Uchida. The Challenge for prediction of drug distribution in brain based on absolute quantification method for membrane proteins. The SNPEE2009 in APSTJ The 24th Annual Meeting, Shizuoka, Japan, May 23, 2009.
  23. Y Uchida. A Rational Application of Targeted Absolute Proteomics for Blood-Brain Barrier Research. Seminar in Universite Paris Descartes, Paris, France, Jan 13, 2009.

.